摘要
目的探讨12项肿瘤标志物蛋白芯片与肺癌病程进展的关系。方法应用酶联免疫技术检测不同临床分期（反映病程进展）的252例肺癌患者及100例体检者（对照组）血清中的12种肿瘤标记物。对体检阳性者隔月复查。结果252例肺癌患者分布在各临床分期中的肿瘤标志物阳性指标（其中有一项指标异常即规定为阳性）所占百分比分别为：0～Ⅰ期（28．6％），Ⅱ期（37．5％），Ⅲ期（57．5％），Ⅳ期（42．9％），不同临床分期的阳性率差异无统计学意义（P〉0．05）。100例对照组中出现阳性6例且均为单一指标，其阳性率为6％，与各临床分期阳性率差异有统计学意义（P〈0．05）。4个月后6例阳性者均为阴性。结论肿瘤标志物对肺癌病程的进展无指导意义，但对体检筛选癌症患者具有很大的意义。
Objective To evaluate the correlation between 12 common tumor markers （TM） and the progress of lung cancer in different stages. Methods The serum levels of 12 tumor markers were determined by ELISA in 252 eases of lung cancer and 100 eases of body examination and then examined the positive of body examination for every two months. Results The positive rates of TM in patients of different stages were （one of them is abnormity will be determined positive） ： 0- Ⅰ （28.8%）; Ⅱ （37.5%）; Ⅲ （57.5%）; Ⅳ（42.9%）, the positive rates of each stages are not different obviously（ P 〉 0.05）. The 6 cases are positive among 100 comparison cases and they all are single mark, the positive rate is 6 percent, the obvious different among every stages （ P 〈 0.05）. The six positive cases all are negative after four months. Conclusion Tumor markers are no meaning to the progress of lung cancer. It is no used for body examination.
出处
《河北医药》
CAS
2008年第4期444-445,共2页
Hebei Medical Journal
关键词
肺癌
肿瘤标志物
蛋白芯片
lung cancer
tumor marker
protein chip
